Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Apogenix AG. (1/7/16). "Press Release: Apogenix Receives First Milestone Payment from Canbridge Licensing Agreement and Signs Amendment to Include Taiwan". Heidelberg.

Region Region Taiwan
Organisations Organisation Apogenix AG
  Organisation 2 Canbridge Life Sciences Ltd. (CN)
Products Product asunercept (APG101)
  Product 2 drug development
Index term Index term Canbridge Life Sciences–Apogenix: cancer drug, 201507– license developm + commercialisation of APG101 in Greater China
Persons Person Höger, Thomas (Apogenix 200511– CEO + CFO before since 10/00 DZ Bank before BASF/Knoll)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that the first milestone of its licensing agreement with CANbridge Life Sciences for the development and commercialization of lead immuno-oncology candidate APG101 in China, Macao, and Hong Kong has been reached, triggering a milestone payment. In addition, Apogenix and CANbridge have signed an amendment to expand the licensed territories to include Taiwan. Apogenix will continue to develop APG101 in all other territories.

An initial biomarker study conducted by CANbridge in Chinese glioblastoma patients revealed a high degree of CD95 ligand expression and confirmed the expression pattern seen in Apogenix’ phase II proof of concept trial in patients with recurrent glioblastoma. APG101 is a CD95 ligand inhibitor which restores the immune response against tumors and inhibits invasive tumor cell growth. In Apogenix’ phase II trial, glioblastoma patients expressing a certain biomarker associated with the CD95 ligand experienced the greatest benefit from treatment with APG101. The median overall survival rate in biomarker-positive patients treated with APG101 more than doubled to 16 months compared to patients treated with radiotherapy alone.

“We are very pleased with CANbridge’s progress and the achievement of the first milestone ahead of schedule,” said Thomas Hoeger, Ph.D., Chief Executive Officer of Apogenix. “Based on the commitment demonstrated by CANbridge and the excellent collaboration throughout our partnership, we have expanded the licensed territories to include Taiwan. We look forward to CANbridge initiating a phase I/II trial with APG101 in newly-diagnosed glioblastoma patients in Taiwan in the second half of this year.”

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.

About APG101

Apogenix’ lead immuno-oncology candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. APG101 is being developed for the treatment of solid tumors and malignant hematological diseases. By blocking the CD95 ligand, APG101 restores the immune response against tumors and inhibits invasive tumor cell growth.


Thomas Hoeger, Ph.D., CEO
Apogenix AG
Phone: +49 (6221) 58 60 80

Media Contacts
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1 (212) 845 4272

Raimund Gabriel
MC Services AG
Phone: +49 (89) 210 228 30

Record changed: 2019-12-03


Picture [iito] Männer Ballett 650x80px

More documents for Apogenix AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Made Without Love 650x80px

» top